Abstract

You have accessJournal of UrologyBladder Cancer: Non-invasive III (MP72)1 Apr 2020MP72-03 ASSESSING THE IMPACT OF ABSENCE OF DETRUSOR MUSCLE IN TA-LG UROTHELIAL CARCINOMA OF THE BLADDER ON RECURRENCE FREE SURVIVAL Riccardo Mastroianni*, Aldo Brassetti, Yazan Al Salhi, Umberto Anceschi, Alfredo Bove, Antonio Carbone, Cosimo De Nunzio, Andrea Fuschi, Mariaconsiglia Ferriero, Antonio Nacchia, Antonio Pastore, Giorgia Tema, Gabriele Tuderti, and Giuseppe Simone Riccardo Mastroianni*Riccardo Mastroianni* More articles by this author , Aldo BrassettiAldo Brassetti More articles by this author , Yazan Al SalhiYazan Al Salhi More articles by this author , Umberto AnceschiUmberto Anceschi More articles by this author , Alfredo BoveAlfredo Bove More articles by this author , Antonio CarboneAntonio Carbone More articles by this author , Cosimo De NunzioCosimo De Nunzio More articles by this author , Andrea FuschiAndrea Fuschi More articles by this author , Mariaconsiglia FerrieroMariaconsiglia Ferriero More articles by this author , Antonio NacchiaAntonio Nacchia More articles by this author , Antonio PastoreAntonio Pastore More articles by this author , Giorgia TemaGiorgia Tema More articles by this author , Gabriele TudertiGabriele Tuderti More articles by this author , and Giuseppe SimoneGiuseppe Simone More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000952.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Obtaining detrusor muscle in TURBt specimen is recommended by European Association of Urology guidelines. Few studies assessed this specific topic in the setting of Ta low-grade (LG) urothelial carcinoma (UC) of the bladder. The aim of this study was to assess if the absence of detrusor muscle at pathologic report has a negative impact on recurrence free probability in patients with a Ta LG UC of the bladder. METHODS: A multicenter TURBt database was queried for: “low-grade Ta, UC of the bladder”. All patients treated between 2008 and 2018 with tumor grade assessed according to both ISUP and WHO grading systems and with a minimum follow-up of 1-yr were included. Patients with previous history of high-grade UC were excluded. Baseline demographic, clinical and pathologic data were analyzed. EORTC risk group was recorded. Kaplan-Meier analysis was performed to assess the predictive role of clinical and pathologic data on Recurrence-Free Survival (RFS) probability, computed at 12, 36, 60 months after TURBt. RESULTS: Overall, 203 consecutive patients were included. Most of them were men (84%), median age was 69 yrs (IQR: 61-77). Patients and tumors characteristics were reported in Table1. At Kaplan-Meier analysis low-risk EORTC cohort displayed a significantly higher RFS probability compared with intermediate-risk cohort (5-yr probability 89.5% vs 72.4%, respectively; log-rank p=0.011. Figure 1a). At univariable Cox regression multiple tumors (HR 1.36, 95%CI 1.02-1.82; p=0.037), tumor diameter ≥3cm (HR 2.8, 95%CI 1.01-7.9; p=0.049), previous history of UC ≤1 yr (HR 1.96, 95%CI 1.02-3.75; p=0.043) and combined EORTC risk group (HR 3.15, 95%CI 1.23-8; p=0.017) were significant predictors of recurrence. Absence of detrusor muscle at pathologic report (HR 1.45, 0.61-3.45; p=0.4. Figure 1b) and adjuvant intravesical treatments (HR 0.95, 95%CI 0.5-1.78; p=0.87) had negligible impacts on RFS probabilities (Table 2). CONCLUSIONS: EORTC risk group is a strong predictive tool to assess the risk of recurrences in patients with Ta-LG UC of the bladder. Absence of detrusor muscle in the TURBt specimen has negligible role on recurrence of patients with Ta-LG tumors, therefore it should no longer be considered as a mandatory data to assess prognosis or treatment schedule. Source of Funding: none © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1073-e1074 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Riccardo Mastroianni* More articles by this author Aldo Brassetti More articles by this author Yazan Al Salhi More articles by this author Umberto Anceschi More articles by this author Alfredo Bove More articles by this author Antonio Carbone More articles by this author Cosimo De Nunzio More articles by this author Andrea Fuschi More articles by this author Mariaconsiglia Ferriero More articles by this author Antonio Nacchia More articles by this author Antonio Pastore More articles by this author Giorgia Tema More articles by this author Gabriele Tuderti More articles by this author Giuseppe Simone More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call